Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO

CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in full force here, with plenaries and poster sessions as packed as before the pandemic.   

The big news from the first few days is that the AstraZeneca drug Tagrisso cuts deaths in half when given to non-small cell lung cancer patients with an EGFR mutation after surgery. That means that over five years, one more patient out of every 10 would still be alive.

Hopeful results were presented for patients with glioma, a type of brain cancer that tends to strike people in middle age. The drug vorasidenib, made by Servier, decreased the growth of grade 2 glioma tumors by 61%, meaning that it slowed the time it took tumors to be classified as progressing to 27.7 months, rather than 11.1 months for those who took a placebo. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In